Glepidotin B exhibits significant antitumor activity, particularly in inhibiting the proliferation of various cancer cell lines. It functions by interfering with microtubule dynamics, which disrupts mitotic spindle formation during cell division, leading to cell cycle arrest and apoptosis. This mechanism makes it a promising candidate for development in chemotherapy regimens, especially for solid tumors. Additionally, Glepidotin B has shown synergistic effects when combined with other microtubule-targeting agents, enhancing its cytotoxic potential. Its natural origin and unique structure also support its use as a lead compound in designing novel anticancer drugs with improved efficacy and reduced resistance.